Document is current
Any future updates will be listed below
-
Authors
Ramli, Fitri Fareez
Harmer, Catherine J.
Cowen, Philip J.
Godlewska, Beata R.
-
Funding
Funding for this research was provided by:
Medical Research Council
National University of Malaysia
- License Information
-
More Information
Article History
Received: 25 May 2025
Accepted: 14 November 2025
First Online: 23 November 2025
Declarations
:
: PJC holds a patent on behalf of Oxford University for the use of ebselen in patients with treatment resistant depression. CJH was supported by the NIHR Oxford Health Biomedical Research Centre; she has received consultancy fees from P1vital, Lundbeck, Servier, UCB, Zogenix, J&J, IESO outside of the current work. BRG received consultancy fees from Tiefenbacher Pharmaceuticals. FFR declares no conflicts of interest.
: The study received ethical approval from the Medical Sciences Interdivisional Research Ethics Committee (IDREC), University of Oxford (R82462/RE002). Informed consent was obtained from all participants before the study.
